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Background: Fluralaner, a novel isoxazoline, has both acaricidal and insecticidal activity through potent blockage of
GABA- and L-glutamate-gated chloride channels. This study investigated the in vitro and in vivo effects of fluralaner
exposure on flea (Ctenocephalides felis) reproduction.
Methods: Blood spiked with sub-insecticidal fluralaner concentrations (between 0.09 and 50.0 ng/mL) was fed to
fleas for 10 days using a membrane system. Cessation of reproduction in exposed fleas was assessed using flea
survival, egg hatchability, and control of oviposition, pupae, and flea emergence. Fluralaner efficacy for in vivo
Ctenocephalides (C.) felis control on dogs was assessed using a simulated flea-infested home environment. During a
pre-treatment period, dogs were infested twice on days −28 and −21 with 100 adult unfed fleas to establish a thriving
population by day 0 of the study. On day 0, one group of dogs was treated with fluralaner (Bravecto™; n = 10), while
another group served as negative control (n = 10). Following treatment, dogs were infested three times with 50 fleas
on days 22, 50 and 78 to simulate new infestations. Live flea counts were conducted weekly on all dogs for 12 weeks
starting 1 day before treatment.
Results: Fluralaner potently inhibited flea reproduction capacity in vitro. Oviposition ceased completely at concentrations
as low as 25.0 ng/mL. While no ovicidal effect was observed, fluralaner exerted a larvicidal effect at exceptionally low
concentrations (6.25 ng/mL). In the simulated flea-infested home environment, flea-control efficacy on fluralaner-treated
dogs was >99% at every time point measured for 12 weeks. No adverse events were observed in fluralaner-treated dogs.
Conclusions: Fluralaner completely controls egg laying, larval development and flea reproduction even at sub-
insecticidal concentrations. Oral treatment of dogs with fluralaner is highly effective for eliminating fleas in a simulated
flea-infested home environment.
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Fluralaner is a new molecular entity of the isoxazoline
class that has shown potent acaricidal and insecticidal
activity through a dual mechanism of binding to neuronal
GABA- and glutamate-gated chloride channels in suscep-
tible invertebrates [1,2]. Fluralaner has high selectivity for
arthropods and a very favorable safety profile in verte-
brates including dogs [3]. Oral fluralaner administration* Correspondence: heike.williams@msd.de; youngDVM@yvrs.com
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unless otherwise stated.(Bravecto™) provides 12 weeks efficacy against tick and flea
infestations on dogs [4,5].
Flea-adulticide activity on infested dogs is important,
but represents only part of the flea-control program
needed to effectively eliminate the flea population. The
adult population on the dog represents only approxi-
mately 5% of the total flea infestation in a dwelling, while
the other 95% of the population consists of eggs, larvae
and pupae in the dog’s home environment [6]. These ma-
turing stages will re-infest the dog as they become adults.
Effective flea control needs to include highly potent
adulticide activity that kills fleas quickly after treatment
for immediate relief; maintenance of this high adulticidel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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reproduction [7]. Fluralaner is a systemic insecticide that
kills fleas that feed on treated dogs. The efficacy demon-
strated in field trials for both flea control and reduction
in signs of allergic flea dermatitis, suggests that treated
dogs are exposed to fewer fleas developing from the
environmental population of juvenile fleas [5]. There-
fore, the objective of the in vitro study was to investigate
if fluralaner concentrations below the instant flea-killing
effect were able to inhibit flea reproduction and thus con-
tribute to the control of environmental flea life stages.
Additionally, a simulated home-environment study was
conducted to prove fluralaner’s flea-control properties not
only on the dog but also the external flea population that
would naturally occur in a household containing an
infested animal.
Methods
In vitro membrane-feeding exposure
A membrane-feeding method [8] was modified to assess
the impact of fluralaner exposure on flea reproduction.
Defibrinated sheep blood was prepared in a series of di-
lutions with fluralaner to obtain concentrations between
50.0 and 0.09 ng/mL. Test solutions were prepared twice
and each preparation was tested in duplicate resulting in
a total of 4 replicates per concentration, along with a
fluralaner-negative solvent control (a solvent concentra-
tion equivalent to that of the highest concentrated flurala-
ner test solution) and an untreated control.
Unfed adult fleas (C. felis; 20 males and 20 females)
were placed into a plastic unit that was then closed with
a gauze lid. A grid inside the plastic unit divided the unit
into 2 chambers, an upper chamber for flea feeding and a
lower chamber for egg collection [8]. Test or control-
blood preparations (2 mL) were placed in an artificial
membrane-closed glass tube that was then placed on the
plastic unit as the food source. Feeding units were incu-
bated (38°C and 60% RH) for 10 days. Test and negative-
control-blood preparations were freshly prepared and ex-
changed (on days 1, 3, 5, and 8) to permit continuous flea
feeding. Fleas were transferred into fresh plastic units on
days 5 and 8 to facilitate egg collection. Collected eggs
were mixed with flea nourishment medium and incubated
(28°C and 80% RH) in darkness for 22 (±3) days to enable
flea development. Parameters recorded were flea survival,
oviposition control, egg hatchability, pupa control and
flea-emergence control.
In vivo study to assess flea-control efficacy in a simulated
home environment
Twenty healthy male and female mixed breed dogs ≥12 weeks
old were housed in individual pens. Ten dogs per group
were randomly assigned to receive either a fluralaner
chewable tablet (Bravecto™) or no treatment. Each pencontained the bottom half of a dog carrier lined with
carpet as bedding. Before treatment, each dog was infested
twice, (28 and 21 days pre-treatment) with 100 adult, un-
fed C. felis to establish a flea population prior to treatment
on each dog. Flea media was added to the carpet four
weeks before the treatment date and weekly thereafter for
the remainder of the study to encourage development of
an active, developing population of juvenile flea stages in
each pen. On the treatment day, dogs in the treated group
received fluralaner at a dose close to 25 mg/kg body
weight by oral administration of one or more flavored
chewable tablets. The chewable tablet(s) were adminis-
tered by placement in the back of the oral cavity over the
tongue to initiate swallowing. Dogs in the negative-control
group remained untreated.
Flea counts were performed on all dogs 1 day before
treatment, 1 day after treatment and then every 7 days
until completion of the study 84 days later. All live fleas
recovered were held and re-infested on the dog after the
comb count was completed. Each dog was also infested
with 50 newly emerged unfed adult fleas on days 22, 50
and 78 to simulate natural infestation post-treatment.
Statistical analysis
The individual dog was the experimental unit and data
from each flea-count time point were analyzed separ-
ately. Flea-count data were transformed [Y = loge(x + 1)]
and analyzed by a mixed linear model including treat-
ment as the fixed effect and block as the random effect.
Kenward-Rogers adjustment was used to determine the
denominator degree of freedom. A two-tailed F-test was
used within the mixed linear model for the comparison
between treatment groups and statistical significance
was declared when P ≤ 0.05. SAS version 9.3 was the pri-
mary software used for analysis.
Efficacy was calculated using arithmetic and geometric
means with Abbott’s formula:
Efficacy (%) = 100 × (MC - MT)/MC, where MC was the
arithmetic or geometric mean number of total adult live
fleas on untreated dogs and MT the arithmetic or geomet-
ric mean number of total adult live fleas on treated dogs.
The study was conducted in California, USA in compli-
ance with the Animal Welfare Act as overseen by the
United States Department of Agriculture (USDA) and eth-
ical approval was obtained before the start. The study was
approved by the Institutional Animal Care and Use
Committee (IACUC no. S11453-00).
Results
Impact on flea reproduction after in vitro
membrane-feeding exposure
Feeding exposure to concentrations of 50 ng fluralaner/mL
resulted in a flea survival of 78.1% (day 2), 20.0% (day 3),
8.7% (day 4) and 1.2% (day 5). At 25 ng/mL flea survival
Table 1 Flea survival after feeding on blood containing





2 3 4 5 8 9 10
50.0 78.1 20.0 8.7 1.2 0 0 0
25.0 90.6 67.5 31.9 11.3 0 0 0
12.5 100 100 67.5 38.9 21.7 17.9 12.3
6.25 100 100 97.5 92.8 85.0 73.1 69.7
3.13 100 100 98.7 97.8 83.1 79.5 78.8
1.56 100 100 99.4 99.1 93.9 92.9 90.3
0.78 100 100 100 100 100 100 100
0.39 100 100 100 100 100 100 98.7
0.19 100 100 100 100 100 100 100
0.09 100 100 100 100 100 100 100
aNo flea counts were performed on exposure days 6 and 7.
Table 3 Flea larvae emergence from eggs of parent fleas






3 4 5 8 9 10
50.0 NA NA NA NA NA NA
25.0 NA NA NA NA NA NA
12.5 no NA NA yes yes NA
6.25 yes yes yes yes yes yes
3.13 yes yes yes yes yes yes
1.56 yes yes yes yes yes yes
0.78 yes yes yes yes yes yes
0.39 yes yes yes yes yes yes
0.19 yes yes yes yes yes yes
0.09 yes yes yes yes yes yes
aNo assessment of larval emergence was performed on exposure days 6 and 7.
NA: not applicable because fleas were either killed or did not lay eggs (Table 1
and Table 2).
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11.3% (day 5). The flea survival rates increased at lower
concentrations (Table 1). Concentrations of 50 and 25 ng
fluralaner/mL achieved complete control of oviposition
(100%), because fleas that survived 4 to 5 days of feeding at
these concentrations did not produce any eggs. At lower
concentrations of 12.5 and 6.25 ng fluralaner/mL, the ovi-
position was controlled by 99.6% and 80.6%, respectively
(Table 2). Fluralaner did not affect the hatching of larvae,
as hatch was observed in almost all flea groups that were
able to lay eggs (Table 3). The pupal development was
strongly reduced (85.1% at 12.5 ng fluralaner/mL, 88.7% at
6.25 ng fluralaner/mL) indicating that fluralaner exposure
has a potent larvicidal effect (Table 4). The same effectTable 2 Flea oviposition control after feeding on blood





3 4 5 8 9 10 Meanb
50.0 100 100 100 NA NA NA 100
25.0 100 100 100 NA NA NA 100
12.5 99.6 100 100 98.9 99.1 100 99.6
6.25 82.6 85.9 81.3 79.9 67.5 86.4 80.6
3.13 32.0 35.7 43.1 70.5 59.9 62.0 50.5
1.56 0 0 17.3 49.8 30.1 29.2 21.1
0.78 8.7 3.0 13.8 12.5 0 18.5 9.4
0.39 6.72 22.8 23.2 23.8 0 20.3 16.1
0.19 0 5.1 21.0 15.1 0 13.9 9.2
0.09 0 11.3 10.9 16.7 0.3 8.1 7.9
aNo egg counts were performed on exposure days 6 and 7.
bArithmetic mean.
NA: not applicable because all fleas were killed (Table 1).continued through to 100% control of adult emergence at
12.5 ng fluralaner/mL (Table 5).
In vivo flea-control efficacy in a simulated home
environment
No adverse events were observed in any fluralaner
(Bravecto™) treated dog following administration. Mean
flea counts (arithmetic/geometric) on untreated-control
dogs were 52.3/26.4 fleas before the day of treatment
(day −1) and in the range of 5.1/1.8 to 57.1/40.6 fleasTable 4 Pupal development control from eggs of parent




Pupal development control (%)
Exposure daya
3 4 5 8 9 10 Meanb
50.0 NA NA NA NA NA NA NA
25.0 NA NA NA NA NA NA NA
12.5 100 NA NA 55.2 100 NA 85.1
6.25 90.2 92.4 87.3 86.4 89.9 86.0 88.7
3.13 66.3 68.9 61.7 70.3 62.1 57.4 64.5
1.56 35.3 36.3 34.6 35.5 41.6 27.2 35.1
0.78 7.5 11.4 16.7 10.8 11.9 14.5 12.1
0.39 9.8 0 1.5 3.3 6.3 0.8 3.6
0.19 8.8 0.2 6.8 0 2.7 0 3.1
0.09 9.1 4.5 1.4 0 5.9 2.9 4.0
aNo pupal counts were performed on exposure days 6 and 7.
bArithmetic mean.
NA: not applicable because fleas were either killed or did not lay eggs (Table 1
and Table 2).
Table 5 Adult flea emergence control after parent fleas




Adult flea emergence control (%)
Exposure daya
3 4 5 8 9 10 Meanb
50.0 NA NA NA NA NA NA NA
25.0 NA NA NA NA NA NA NA
12.5 NA NA NA 100 NA NA 100
6.25 29.2 0 0 9.2 30.8 0 11.5
3.13 4.4 11.9 3.2 8.6 7.5 0 5.9
1.56 0 0 0 10.2 0 0 1.7
0.78 3.8 0 0 3.1 1.8 0 1.5
0.39 0 0 0 1.6 5.2 0 1.1
0.19 4.6 0 1.3 0.8 6.7 0 2.2
0.09 1.1 0.5 0 0 0 0 0.3
aNo adult flea counts were performed on exposure days 6 and 7.
bArithmetic mean.
NA: not applicable because fleas were either killed or did not lay eggs
(Table 1, Table 2, and Table 4).
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on fluralaner-treated dogs were 35.0/14.1 fleas before
treatment, 0/0 fleas on days 1, 7, 14, 21, 28, 35, 42, 63,
77 and 84, and 0.1/0.1 fleas on days 49, 56, and 70 after
treatment. Compared to control, these counts were sig-
nificantly different (P ≤0.021) on all post-treatment
count days. Calculated efficacy results were either 100%Table 6 Flea-control efficacy on treated dogs (25 mg fluranal
simulated home environment
















aEfficacy calculated from arithmetic/geometric mean flea counts.
NA: not applicable.or very close to 100% at all post-treatment time points
(Table 6).
Discussion
Fluralaner has potent inhibitory effects on C. felis fleas
as demonstrated in the aforementioned in vitro and
in vivo experiments. The control of flea reproduction
prevents the formation of a flea population within a
household. In addition to a field study that showed flura-
laner (Bravecto™) to be effective against fleas on dogs for
12 weeks [5], an in vitro study was performed to investi-
gate the effect of fluralaner on flea reproduction using
sub-insecticidal concentrations.
The fluralaner concentrations tested in this study were
sufficiently low that fleas survived for 2 to 10 days. This
survival duration allows for flea reproduction, as viable
eggs can be produced 24 hours after fleas start feeding.
Fluralaner concentrations tested correlated with the ef-
fects on the reproduction cycle. 50 to 25 ng fluralaner/
mL effectively controlled the oviposition (egg laying),
and 12.5 to 6.25 ng/mL largely reduced the pupal devel-
opment (indicating a strong larvicidal effect). Overall,
sub-insecticidal concentrations as low as 12.5 ng flurala-
ner/mL achieved 100% cessation of flea reproduction,
illustrating that fluralaner provides dog owners’ with
additional protection against re-infestation of their pets
in the home environment.
The potent in vitro effects on flea reproduction substan-
tiate the results of the in vivo study where dogs were
treated with oral fluralaner (Bravecto™) compared toer/kg body weight) compared with untreated dogs in a
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The environment was created by allowing the dogs access
to a carpeted bedding area and heavy flea-challenges dur-
ing the month preceding the fluralaner treatment. This re-
sulted in an environment with a thriving flea population
including all developmental stages before treatment
administration, leading to an increased flea burden on
untreated-control dogs throughout the study duration.
Thus, fleas were permanently present on control dogs
during the study, however, some variability was observed
in flea numbers although the study design should have
provided a high flea burden on controls at all assessment
times. Following treatment, the flea populations were ef-
fectively controlled on the fluralaner (Bravecto™) -treated
dogs, with efficacy at, or near, 100% throughout the 12-
week post-treatment period.
The long-lasting adulticidal activity of fluralaner
(Bravecto™) provides two benefits with respect to flea con-
trol: first, it prevents a sustainable re-infestation of dogs
by offspring from the environment, and second, it pre-
vents new flea eggs from being added to the environment
as female fleas are killed within 8 hours (before they pro-
duce eggs) [9]. Both effects lead to the depletion of the en-
vironmental flea population. The studies described here
indicate that fluralaner’s flea-control capabilities combine
an adulticidal effect with long-term efficacy and, addition-
ally, effective prevention of flea reproduction. This is an
advantage over pure adulticides which are often combined
with an insect-growth regulator (IGR) to provide the same
effect.
Highly effective control of environmental flea popula-
tions has been recorded with topically applied insecticides
[7], but is not reliably achieved with previously evaluated
systemically administered insecticides [10]. Taken together
the results of both the in vitro and in vivo studies support
the claims of fluralaner’s effective flea control properties.
In addition to the fast flea killing effect within 8 hours [9]
the studies indicate that fluralaner, a systemic flea treat-
ment, is successful in controlling developing flea popula-
tions in the environment.
The efficacy of monthly treatments is dependent on dog
owner compliance. It has recently been shown that owner
compliance with monthly re-treatment recommendations
is weak [11] which may jeopardize flea control. The results
reported here provide evidence that a single systemic flur-
alaner treatment (Bravecto™) provides 12 weeks of flea-
population control and is a valuable new tool for achieving
effective and long-term flea control for dogs and their
homes.
Conclusions
Fluralaner is a potent inhibitor of flea reproduction at
various developmental stages and at exposure levels that
are far below its immediate insecticidal activity. Thus,fluralaner treatment disrupts the flea-breeding cycle and
protects dogs and their homes from flea infestations over
a 12-week period without additional premise treatment.
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